Cartesian Therapeutics (RNAC) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$19.5 million.
- Cartesian Therapeutics' Income towards Parent Company fell 3010.27% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.7 million, marking a year-over-year increase of 5991.61%. This contributed to the annual value of -$77.4 million for FY2024, which is 6476.08% up from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' Income towards Parent Company is -$19.5 million, which was down 3010.27% from -$20.1 million recorded in Q2 2025.
- Cartesian Therapeutics' 5-year Income towards Parent Company high stood at $15.0 million for Q2 2024, and its period low was -$196.7 million during Q4 2023.
- For the 5-year period, Cartesian Therapeutics' Income towards Parent Company averaged around -$17.4 million, with its median value being -$12.2 million (2024).
- Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 550566.8% in 2022, then crashed by 343714.58% in 2023.
- Quarter analysis of 5 years shows Cartesian Therapeutics' Income towards Parent Company stood at $12.2 million in 2021, then plummeted by 51.85% to $5.9 million in 2022, then plummeted by 3437.15% to -$196.7 million in 2023, then surged by 87.66% to -$24.3 million in 2024, then rose by 19.6% to -$19.5 million in 2025.
- Its Income towards Parent Company stands at -$19.5 million for Q3 2025, versus -$20.1 million for Q2 2025 and -$19.9 million for Q1 2025.